Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Sebastian Haferkamp
Observed names:
Haferkamp, S.,
Haferkamp, Sebastian,
S. Haferkamp
Institutions:
University Hospital Regensburg,
University Hospital in Halle,
Martin Luther University Halle-Wittenberg
Observed institutions:
University Hospital Regensburg,
University Hospital in Halle,
University of Regensburg,
Martin Luther University Halle-Wittenberg
ORCID:
0000-0002-3894-8345
Observed ORCID:
0000-0002-3894-8345
OpenAlex ID:
A5134030231
787O Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial
2022
·
J.C. Becker
, S. Ugurel
, et al.
·
Annals of Oncology
·
10
Treatment patterns in geriatric patients with melanoma and the effect of age on the efficacy of immunotherapy: Analysis from the real-world multicenter registry ADOREG
2026
·
Konstantinos Lallas
, Lena Nanz
, et al.
·
European Journal of Cancer
·
3
Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients
2026
·
Alexander Scheiter
, Simon Mellin
, et al.
·
BMC Medicine
·
2
Immune effector cell‐associated neurotoxicity syndrome (ICANS) during tebentafusp in metastatic uveal melanoma
2026
·
Laura Schreieder
, Laura Jockel
, et al.
·
JDDG Journal der Deutschen Dermatologischen Gesellschaft
Survivorship care for melanoma patients: a scoping review
2026
·
Madlen Hörold
, Sasha Schutkowski
, et al.
·
Journal of Cancer Survivorship
PDF
Real‐world effectiveness and safety with nivolumab plus ipilimumab or nivolumab alone in patients with or without melanoma brain metastasis: Results from the German noninterventional NICO study
2026
·
Ralf Gutzmer
, Michael Weichenthal
, et al.
·
International Journal of Cancer
Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients
2026
·
Scheiter, Alexander
, Mellin, Simon
, et al.
·
University of Regensburg Publication Server (University of Regensburg)
PDF
Micrometastasis-derived models enable drug testing for early-stage, high-risk melanoma patients
2026
·
Weidele, Kathrin
, Werno, Christian
, et al.
·
Fraunhofer-Publica (Fraunhofer-Gesellschaft)
Neoadjuvant intralesional daromun (L19IL2/L19TNF) improves outcomes in resectable, relapsed, locally advanced melanoma regardless of prior therapy: subgroup analyses from the randomized phase 3 trial PIVOTAL
2026
·
J.C. Hassel
, A. Hauschild
, et al.
·
EJC Skin Cancer
Socioeconomic situation in Long-Term Survivors of Stage IV Melanoma
2026
·
M. Reitmajer
, E. Livingstone
, et al.
·
EJC Skin Cancer
Long-Term Survivors With Melanoma Brain Metastases: Clinical Burden and Psychosocial Distress
2026
·
M. Reitmajer
, E. Livingstone
, et al.
·
EJC Skin Cancer
Intralesional L19IL2/L19TNF in high-risk lacSCC patients: results from the Phase II DUNCAN Trial Exploratory Cohort
2026
·
T. Eigentler
, A. Cozzio
, et al.
·
EJC Skin Cancer
PDF
Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients
2026
·
Scheiter, Alexander
, Mellin, Simon
, et al.
·
Fraunhofer-Publica (Fraunhofer-Gesellschaft)
Étude de phase 3 (PIVOTAL) sur le daromun intralésionnel néoadjuvant comparé à une chirurgie immédiate dans le mélanome entièrement résécable avec métastases cutanées régionales et/ou ganglionnaires
2024
·
C. Robert
, J.C. Hassel
, et al.
·
Annales de Dermatologie et de Vénéréologie - FMC
Encorafenib plus Binimetinib in Patients with locally advanced, inoperable, or metastatic BRAFV600 mutated Melanoma : First Data from the multicenter, multinational, prospective, non-interventional Longitudinal Study BERINGMELANOM
2020
·
Richtig, E.
, Debus, D.
, et al.
·
Archive ouverte UNIGE (University of Geneva)
Show more works
View as search
Works count:
15
Citation count:
15
H-index:
2
I10-index:
1
Year
Topic
Type